Theodorou I - Search Results

1

Influence of the R22H variant of macrophage inflammatory protein 1beta/Lag-1 in HIV-1 survival.

Capoulade-Métay C, Meyer L, Tran T, Persoz A, Bourdais A, Dudoit Y, Delfraissy JF, Debré P, Theodorou I. Capoulade-Métay C, et al. Among authors: theodorou i. AIDS. 2005 May 20;19(8):831-3. doi: 10.1097/01.aids.0000168979.97584.18. AIDS. 2005. PMID: 15867499

2

New CCR5 variants associated with reduced HIV coreceptor function in southeast Asia.

Capoulade-Métay C, Ma L, Truong LX, Dudoit Y, Versmisse P, Nguyen NV, Nguyen M, Scott-Algara D, Barré-Sinoussi F, Debré P, Bismuth G, Pancino G, Theodorou I. Capoulade-Métay C, et al. Among authors: theodorou i. AIDS. 2004 Nov 19;18(17):2243-52. doi: 10.1097/00002030-200411190-00004. AIDS. 2004. PMID: 15577536

3

Biochemical and HIV-1 coreceptor properties of K26R, a new CCR5 Variant in China's Sichuan population.

Ma L, Dudoit Y, Tran T, Xing H, Chen J, Pancino G, Bismuth G, Debré P, Shao Y, Theodorou I, Capoulade-Métay C. Ma L, et al. Among authors: theodorou i. J Acquir Immune Defic Syndr. 2005 May 1;39(1):38-43. doi: 10.1097/01.qai.0000158761.71165.e9. J Acquir Immune Defic Syndr. 2005. PMID: 15851912

4

Deleterious genetic influence of CX3CR1 genotypes on HIV-1 disease progression.

Faure S, Meyer L, Genin E, Pellet P, Debré P, Théodorou I, Combadière C; SEROCO Study Group. Faure S, et al. Among authors: theodorou i. J Acquir Immune Defic Syndr. 2003 Mar 1;32(3):335-7. doi: 10.1097/00126334-200303010-00014. J Acquir Immune Defic Syndr. 2003. PMID: 12626895

5

A natural CCL5/RANTES variant antagonist for CCR1 and CCR3.

Capoulade-Métay C, Ayouba A, Kfutwah A, Lole K, Pêtres S, Dudoit Y, Deterre P, Menu E, Barré-Sinoussi F, Debré P, Theodorou I. Capoulade-Métay C, et al. Among authors: theodorou i. Immunogenetics. 2006 Jul;58(7):533-41. doi: 10.1007/s00251-006-0133-2. Epub 2006 Jun 22. Immunogenetics. 2006. PMID: 16791620

6

CCR5 delta32 deletion and reduced risk of toxoplasmosis in persons infected with human immunodeficiency virus type 1. The SEROCO-HEMOCO-SEROGEST Study Groups.

Meyer L, Magierowska M, Hubert JB, Mayaux MJ, Misrahi M, Le Chenadec J, Debre P, Rouzioux C, Delfraissy JF, Theodorou I. Meyer L, et al. Among authors: theodorou i. J Infect Dis. 1999 Sep;180(3):920-4. doi: 10.1086/314933. J Infect Dis. 1999. PMID: 10438395

7

Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1.

Faure S, Meyer L, Costagliola D, Vaneensberghe C, Genin E, Autran B, Delfraissy JF, McDermott DH, Murphy PM, Debré P, Théodorou I, Combadière C. Faure S, et al. Among authors: theodorou i. Science. 2000 Mar 24;287(5461):2274-7. doi: 10.1126/science.287.5461.2274. Science. 2000. PMID: 10731151

8

CCR5 delta32 deletion and response to highly active antiretroviral therapy in HIV-1-infected patients.

Guérin S, Meyer L, Theodorou I, Boufassa F, Magierowska M, Goujard C, Rouzioux C, Debré P, Delfraissy JF; SEROCO/HEMOCO Study Group. Guérin S, et al. Among authors: theodorou i. AIDS. 2000 Dec 1;14(17):2788-90. doi: 10.1097/00002030-200012010-00020. AIDS. 2000. PMID: 11125899 No abstract available.

9

[Chemokines and immunomodulation: applications for HIV infections].

Théodorou I, Combadière C, Faure S, Debré P. Théodorou I, et al. J Soc Biol. 2002;196(1):7-11. J Soc Biol. 2002. PMID: 12134637 Review. French.

10

Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.

Laurichesse JJ, Persoz A, Theodorou I, Rouzioux C, Delfraissy JF, Meyer L. Laurichesse JJ, et al. Among authors: theodorou i. HIV Med. 2007 May;8(4):213-9. doi: 10.1111/j.1468-1293.2007.00455.x. HIV Med. 2007. PMID: 17461848 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

177 results

Search Page